Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer—an international, multicentre, real-world analysis

Background: This study explores the potential benefits of neoadjuvant chemotherapy in borderline resectable (BR) pancreatic adenocarcinoma. Despite neoadjuvant treatment (NAT) increasingly being utilised, uncertainty remains as to the optimal approach. Patients and methods: This study assessed clini...

Full description

Bibliographic Details

Published in:	ESMO Real World Data and Digital Oncology
Main Authors:	S. Banks, W. Hong, K. Degeling, J. Shapiro, B. Thomson, H.S. Ko, S. Ananda, A. Jalali, Y.H. To, B. Loveday, S.-A. McLachlan, B. Knowles, A. Fox, M. Michael, R. Wong, M. Burge, K. Clarke, S. Pattison, M. Nikfarjam, R. Zielinski, F. Day, C.E. Chee, A. Nagrial, M. IJzerman, P. Gibbs, B. Lee
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Subjects:	pancreatic cancer neoadjuvant borderline resectable data registry real-world data
Online Access:	http://www.sciencedirect.com/science/article/pii/S294982012300022X